Cervica cancer and human papillomavirus: Epidemiological evidence and perspectives for prevention

Salud Publica de Mexico

Volumn 39, Issue 4, 1997, Pages 274-282

  Muñoz, Nubia ^a   Xavier Bosch, F ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

Cervix neoplasms prevention and control; Papillomavirus, human; Review

Indexed keywords

ARTICLE; CANCER CONTROL; DEVELOPING COUNTRY; FEMALE; HUMAN; PREVALENCE; RISK FACTOR; UTERINE CERVIX CANCER; WART VIRUS; CARCINOMA IN SITU; CASE CONTROL STUDY; COHORT ANALYSIS; EUROPE; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; SEXUAL BEHAVIOR; SEXUALITY; STATISTICS; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

VIRUS DNA;

CARCINOMA IN SITU; CASE-CONTROL STUDIES; COHORT STUDIES; DEVELOPING COUNTRIES; DNA, VIRAL; EUROPE; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SEXUAL BEHAVIOR; SEXUAL PARTNERS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0030612090     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0036-36341997000400005     Document Type: Article

References (31)

1. Pisani P, Parkin DM, Muñoz N, Ferlay J. Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev. En prensa.
2. Muñoz N, Bosch FX, Kaldor JM. Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. Br J Cancer 1988;57:1-5.
3. Muñoz N, Bosch FX. Current views on the role of human papillomavirus in the genesis of cervical neoplasia. Papillomavirus Report 1991;2:57-60.
4. Muñoz N. HPV and cervical cancer: Epidemiological evidence. Proceedings of EUROGIN/WHO joint experts meeting on cervical cancer screening and new developments; 1996 june 17-19; Ginebra, Suiza. París: EUROGIN Scientific Publications, 1997. En prensa
5. International Agency for Research on Cancer. Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Human papillomaviruses. Lyon: IARC 1995; vol. 64.
6. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
7. Bosch FX, Muñoz N, De Sanjosé S, Navarro C, Moreo P, Ascunce N et al. Human papillomavirus and cervical intraepithelial neoplasia grade III/ carcinoma in situ: A case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993;2:415-422.
8. Schiffman M, Bauer H, Hoover R, Glass A, Cadell d, Rush B et al. Epidemiologic evidence showing that HPV infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-964.
9. Becker TM, Wheeler CM, McGough NS, Parmenter CA, Jordan SW, Stidley CA et al. Sexually transmited diseases and other risk factors for cervical dysplasia among southwestern Hispanic and non-Hispanic white women. J Am Med Assoc 1994;271:1181-1188.
10. Olsen AO, Gjoen K, Sauer T, Osterstavik I, Naess O, Kjerulf K et al. Human papillomavirus and cervical intraepithelial neoplasia grade II-III: A population-based case-control study. Int J Cancer 1995;61:312-315.
11. Liaw K-L, Hsing AW, Chen C-J, Schiffman MH, Zhang TY, Hsieh C-Y et al. Human papillomavirus and cervical neoplasia. A case-control study in Taiwan. Int J Cancer 1995;62:565-571.
12. Guerrero E, Daniel RW, Bosch FX, Castellsagué X, Muñoz N, Gili M et al Comparison of virapap, southern hybridization and polymerase chain reaction methods for human papillomavirus identification in an epidemiological investigation of cervical cancer. J Clin Microbiol 1992;30:2951-2959
13. Muñoz N, Bosch FX, De Sanjosé S, Tafur L, Izarzugaza I, Gili M et al. The causal link between human papillomavirus and invasive cervical cancer: A population-based case-control study in Colombia and Spain. Int J Cancer 1992;52:743-749.
14. Eluf-Neto J, Booth M, Muñoz N, Bosch FX, Meijer CJLM, Walboomers JMM. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994;69:114-119.
15. Peng H, Liu S, Mann V, Rohan T, Rawls W. Human papillomavirus types 16 and 33, herpes simplex virus type 2 and other risk factors for cervical cancer in Sichuan Province, China. Int J Cancer 1991;47:711-716.
16. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:272-278.
17. Liu T, Soong S-J, Alvarez RD, Butterworth CE. A longitudinal analysis of human papillomavirus 16 infection, nutritional status, and cervical dysplasia progression. Cancer Epidemiol Biomarkers Prev 1995;4:373-380.
18. Ho GYF, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P et al. Persistent genital human papillomavirus infection as risk factors for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-1371.
19. Remmink AJ, Walboomers JMM, Heimerhorst TJM, Voorhorst FJ, Rozendaal L, Risse EKJ. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. Int J Cancer 1995;61:306-311.
20. Woodman CBJ, Rollason T, Ellis J, Jierney R, Wilson S, Young L. Human papillomavirus infection and risk of progression of epithelial abnormalities of the cervix. Br J Cancer 1996;73:553-556.
21. Chua K-L, Hjerpe A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 1996;77:121-127.
22. Xi LF, Koutsky LA, Galloway DA, Kuypers J, Hughes JP, Wheeler CM et al. Risk of cervical intraepithelial neoplasia grade 2-3 (CIN 2-3) in relation to human papillomavirus type 16 variants. Proceedings of the 15th International papillomavirus Workshop; 1996 December 1-6; Brisbane, Australia; Abstract núm. 20:68.
23. Muñoz N, Bosch FX, De Sanjosé S, Vergara A, Del Moral A, Muñoz MT et al Risk factors for cervical intraepithelial neoplasia grade III/carcinoma in situ in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993;2:423-431
24. Bosch FX, Muñoz N, De Sanjosé S, Izarzugaza I, Gili M, Viladiu P et al. Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 1992;52:750-758.
25. Horeno V, Muñoz N, Bosch FX, De Sanjosé S, González LC, Tafur L et al. Risk factors for progression of cervical intraepithelial neoplasm grade III to invasive cervical cancer. Cancer Epidemiol Biomarkers Prev 1995;4:459-467.
26. Skegg DC, Corwin PA, Paul C, Doll R. Importance of the male factor in cancer of the cervix. Lancet 1982;2:581-583.
27. Bosch FX, Castellsagué X, Muñoz N, De Sanjosé S, Ghaffari AM, Gonzalez LC et al. Male sexual behavior and human papillomavirus DNA: Key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996;88:1060-1067.
28. Bosch FX, Muñoz M, De Sanjosé S, Guerrero E, Ghaffari T, Kaldor J et al. Importance of the human papillomavirus endemicity in the incidence of cervical cancer: An extension of the hypotesis on sexual behaviour. Cancer Epidemiol Biomarkers Prev 1994;3:375-379
29. Muñoz N, Castellsagué X, Bosch FX, Tafur L, De Sanjosé S, Aristizabal N et al. Difficulty in elucidating the male role in Colombia, a high-risk area for cervical cancer. J Natl Cancer Inst 1996;88:1068-1075.
30. Muñoz N, Crawford L, Coursaget P. HPV vaccines for cervical neoplasia. Lancet 1995;345:249.
31. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddow P et al. Human papillomavirus testing in primary cervical screening. Lancet 1995;345: 1533-1536.